Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FolSmart: FBL-MTX Phase 1 SAD in Healthy Subjects
NCT05117593Phase 1Completed
- Sponsor
- Solfarcos
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing FBL-MTX with Placebo (2 arms). Primary endpoints: Change from baseline in systolic blood pressure at 1 month, Change from baseline in diastolic blood pressure at 1 month and 7 more. Started Jun 2021; status: completed.
02
Drugs
FBL-MTX
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05117593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117593.